Evidence map›Paper›PMID 22545737›Full record

Trial reportJournal of consulting and clinical psychology2012

Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial.

Steven A Safren, Conall M O'Cleirigh, Jacqueline R Bullis, Michael W Otto, Michael D Stein, Mark H Pollack

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of consulting and clinical psychology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 16 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 16 syntheses or guidelines pooled it, 224 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Guideline
  13. Pooled it
  14. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2014
    Pooled it
  15. Pooled it
  16. Pooled it
  17. Trial
  18. Trial
  19. Trial
  20. Trial

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Steven A SafrenMassachusetts General Hospital. ssafren@partners.org
Conall M O'Cleirigh
Jacqueline R Bullis
Michael W Otto
Michael D Stein
Mark H Pollack
Massachusetts General Hospital · USBoston University · USHarvard University · USJohn Brown University · US

Funding

CBT for depression &adherence in HIV methadone patientsR01DA018603 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI SAFREN, STEVEN A · 2004 to 2008
$2.9M
NIDA NIH HHS R01 DA018603NIDA NIH HHS R01DA018603
6 · The paper itself

Abstract

objectiveDepression and substance use, the most common comorbidities with HIV, are both associated with poor treatment adherence. Injection drug users comprise a substantial portion of individuals with HIV in the United States and globally. The present study tested cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with HIV and depression in active substance abuse treatment for injection drug use.

methodThis is a 2-arm, randomized controlled trial (N = 89) comparing CBT-AD with enhanced treatment as usual (ETAU). Analyses were conducted for two time-frames: (a) baseline to post-treatment and (b) post-treatment to follow-up at 3 and 6 months after intervention discontinuation.

resultsAt post-treatment, the CBT-AD condition showed significantly greater improvement than ETAU in MEMS (electronic pill cap) based adherence, γslope = 0.8873, t(86) = 2.38, p = .02; dGMA-raw = 0.64, and depression, assessed by blinded assessor: Mongomery-Asberg Depression Rating Scale, F(1, 79) = 6.52, p < .01, d = 0.55; clinical global impression, F(1, 79) = 14.77, p < .001, d = 0.85. After treatment discontinuation, depression gains were maintained, but adherence gains were not. Viral load did not differ across condition; however, the CBT-AD condition had significant improvements in CD4 cell counts over time compared with ETAU, γslope = 2.09, t(76) = 2.20, p = .03, dGMA-raw = 0.60.

conclusionsIn patients managing multiple challenges including HIV, depression, substance dependence, and adherence, CBT-AD is a useful way to integrate treatment of depression with an adherence intervention. Continued adherence counseling is likely needed, however, to maintain or augment adherence gains in this population.

Indexed as

Cognitive Behavioral TherapyAgedAntiretroviral Therapy, Highly ActiveDepressive DisorderFemaleHIV InfectionsHumansMaleMedication AdherenceMiddle AgedSubstance Abuse, IntravenousSubstance-Related DisordersTreatment Outcome

Identifiers

PMID22545737
PMCPMC3365619
OpenAlexW2169304720

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.